Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that The New England Journal of
medicine published landmark results of a Nexavar
study in liver
cancer. The data of the Phase III trial showed that Nexavar® (sorafenib) tablets decreased the absolute risk of death by 31 percent in
patients with unresectable hepatocellular carcinoma (HCC), or liver
cancer, versus patients who received placebo.
A minimally invasive treatment for a common cause of male infertility can significantly
improve a couple's chances for pregnancy, according to a new
study published in the August issue of Radiology .